Alexis R. Ogdie, MD, MSCE
Rheumatology
Accepting new patients
Sees patients age 18 and up
Penn Rheumatology Perelman
Schedule onlineCall 215-662-4333
Headshot of Alexis R. Ogdie, MD, MSCE
Penn Medicine Provider

About me

  • Director, Center for Clinical Epidemiology and Biostatistics
  • Director, Penn Psoriatic Arthritis and Spondyloarthritis Program
  • Professor of Medicine (Rheumatology) at the Hospital of the University of Pennsylvania
  • Associate Professor of Epidemiology in Biostatistics and Epidemiology
  • Professor of Biostatistics and Epidemiology

Dr. Ogdie's research program is focused on inflammatory arthritis (IA) including psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), and rheumatoid arthritis (RA). The mission of her research program is to improve outcomes in IA by accelerating diagnosis, increasing the focus on meaningful, patient-centered outcomes, and developing and advancing methods for precision medicine. Dr. Ogdie is an expert in the care of patients with IA, Director of the Penn Psoriatic Arthritis and Spondyloarthritis Program and Director of the Penn Center for Clinical Epidemiology and Biostatistics.

Her areas of expertise include epidemiology and pharmacoepidemiology, biostatistical methods for observational studies (e.g., complex time to event modeling, prediction modeling), outcome measures (e.g., qualitative and quantitative/psychometric assessment), clinical trial design and more general qualitative methods (e.g., survey, focus group and interview studies). Her recent work has focused on a) pragmatic trial design and implementation including the recent launch of a first head-to-head pragmatic trial in PsA (EVOLUTION, NCT05669833); b) trials aimed at improving outcomes in PsA through holistic care including a trial to test Dietary Interventions in PsA (DIPSA, NCT04180904), and a new single arm trial to address whole patient care as a novel care paradigm in rheumatology (funded by a Rheumatology Research Foundation) and c) identifying risk factors for development of PsA among patients with psoriasis.

Education and training

  • Medical School: Georgetown University School of Medicine
  • Residency: University of Pennsylvania Health System
  • Fellowship: University of Pennsylvania Health System

What my patients think about me

Average Rating

245 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
February 2026
professional
Anonymous
February 2026
knowledgeable, kind, and supportive care. has always offered next steps when solutions/medicine not working well
Anonymous
February 2026
she is a dedicated dr
Anonymous
January 2026
dr. ogdie helps me understand the science and data behind her recommendations. i really appreciate that.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Ogdie is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Nikiphorou E, Ogdie A, Twigg D, Quiñones E, Ling YL, Cappelleri JC, Sanchez-Riera L, Masri KR, Hughes M, Massey N. Treatment satisfaction, disease severity, and health-care use in patients with axial spondyloarthritis in the United States and Europe , Rheumatology (Oxford), 65: 2026,keag106

Ogdie A, Middaugh N, Marchese M, Walsh JA, Bello N, Ngantcha M, Kronbergs A, Grace EL, Mease PJ. Cycling to TNFi vs. Switching to IL-17Ai Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World CorEvitas PsA/SpA Registry Data , Adv Ther: 2026

Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, Chan D, Chakravarty SD, Langholff W, Wang Y, Shao J, Krol Y, Gottlieb AB. Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE Study , Arthritis Rheumatol: 2026

Mease P, Ye X, Saffore CD, Parikh B, Ciecinski S, Blachley T, Eliot M, Middaugh N, Ogdie A. Quantifying Disease Activity Despite Treatment with Tumor Necrosis Factor Inhibitors Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World Results from the PPD CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry , Rheumatol Ther: 2026

Leung YY, Haugegaard T, Annfeldt TK, Holland R, Strand V, Mease P, Tugwell P, Wells GA, Shea BJ, Mathew AJ, Goel N, Lindsay C, Ogdie A, Orbai AM, Coates LC, Gladman DD, Tillett W, Chau J, Christensen R. Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: A meta-epidemiological study , Semin Arthritis Rheum: 2026

Gladman DD, Eder L, Selmi C, Mease PJ, Ogdie A, Lozenski K, Adamson E, Sharaf M, Rampakakis E, Pina Vegas L, Coates LC. Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials , Rheumatol Ther: 2025

Thrastardottir T, Bjornsson AH, Ogdie A, Hauksdottir A, Kristinsson SY, Gudbjornsson B, Love TJ; ICEBIO. Antimicrobial Use and Serious Infections Among Patients With Psoriatic Arthritis After Initiating Tumor Necrosis Factor Inhibitors: A Nationwide Matched Cohort Study , J Rheumatol, 53: 2025,232

Ogdie A, Middaugh N, Blachley T, Bourgeois T, Ling YL, Mundayat R, Fallon L, Masri KR, Mease PJ. Effectiveness of Tofacitinib in Patients with Psoriatic Arthritis Initiating Monotherapy Versus Combination Therapy: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry , Rheumatol Ther: 2025

Gossec L, Balanescu A, D'Agostino MA, Ogdie A, Sewerin P, Deng Y, Shi L, Sugimoto Y, Zhong S, Xing Y, Lippe R, Kishimoto M. Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials , Arthritis Res Ther: 2025

McInnes IB, Coates LC, Mease PJ, Ogdie A, Kavanaugh A, Eder L, Schett G, Kivitz A, McGonagle D, Brennan N, Godwood A, Cullen E, Reich K, Ritchlin CT, Merola JF. Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial , Nat Med: 2025